Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Steroyl-CoA Desaturase 1 (SCD1) protects ovarian cancer cells from ferroptotic cell death.

Tesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Lee J, Furdui CM, Hegde P, Torti FM, Torti SV.

Cancer Res. 2019 Jul 3. pii: canres.0369.2019. doi: 10.1158/0008-5472.CAN-19-0369. [Epub ahead of print]

PMID:
31270077
2.

A Targeted Mass Spectrometric Assay for Reliable Sensitive Hepcidin Quantification.

Moghieb A, Tesfay L, Nie S, Gritsenko M, Fillmore TL, Jacobs JM, Smith RD, Torti FM, Torti SV, Shi T, Ansong C.

Sci Rep. 2019 May 13;9(1):7264. doi: 10.1038/s41598-019-43756-9.

3.

Winning the war with iron.

Torti SV, Torti FM.

Nat Nanotechnol. 2019 Jun;14(6):499-500. doi: 10.1038/s41565-019-0419-9. No abstract available.

PMID:
30911165
4.

Iron and Cancer.

Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM.

Annu Rev Nutr. 2018 Aug 21;38:97-125. doi: 10.1146/annurev-nutr-082117-051732. Review.

PMID:
30130469
5.

A Systems Biology Approach to Understanding the Pathophysiology of High-Grade Serous Ovarian Cancer: Focus on Iron and Fatty Acid Metabolism.

Konstorum A, Lynch ML, Torti SV, Torti FM, Laubenbacher RC.

OMICS. 2018 Jul;22(7):502-513. doi: 10.1089/omi.2018.0060.

6.

Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer.

Blanchette-Farra N, Kita D, Konstorum A, Tesfay L, Lemler D, Hegde P, Claffey KP, Torti FM, Torti SV.

Oncogene. 2018 Jul;37(29):4013-4032. doi: 10.1038/s41388-018-0243-y. Epub 2018 Apr 26.

7.

Iron-responsive element-binding protein 2 plays an essential role in regulating prostate cancer cell growth.

Deng Z, Manz DH, Torti SV, Torti FM.

Oncotarget. 2017 Jul 17;8(47):82231-82243. doi: 10.18632/oncotarget.19288. eCollection 2017 Oct 10.

8.

Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer.

Deng Z, Manz DH, Torti SV, Torti FM.

Antioxid Redox Signal. 2019 Mar 10;30(8):1043-1061. doi: 10.1089/ars.2017.7023. Epub 2017 Dec 11.

PMID:
29061069
9.

Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease.

Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD.

Cell. 2017 Oct 5;171(2):273-285. doi: 10.1016/j.cell.2017.09.021. Review.

10.

Iron addiction: a novel therapeutic target in ovarian cancer.

Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, Xian W, McKeon F, Lynch M, Crum CP, Hegde P, Brewer M, Wang X, Miller LD, Dyment N, Torti FM, Torti SV.

Oncogene. 2017 Jul 20;36(29):4089-4099. doi: 10.1038/onc.2017.11. Epub 2017 Mar 20.

11.

DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms.

Lemler DJ, Lynch ML, Tesfay L, Deng Z, Paul BT, Wang X, Hegde P, Manz DH, Torti SV, Torti FM.

Breast Cancer Res. 2017 Mar 7;19(1):25. doi: 10.1186/s13058-017-0814-9.

12.

Effects of Anti-repulsive Guidance Molecule C (RGMc/Hemojuvelin) Antibody on Hepcidin and Iron in Mouse Liver and Tumor Xenografts.

Torti SV, Lemler E, Mueller BK, Popp A, Torti FM.

Clin Exp Pharmacol. 2016 Nov;6(6). pii: 223. doi: 10.4172/2161-1459.1000223. Epub 2016 Nov 17.

13.

Activated Oncogenic Pathway Modifies Iron Network in Breast Epithelial Cells: A Dynamic Modeling Perspective.

Chifman J, Arat S, Deng Z, Lemler E, Pino JC, Harris LA, Kochen MA, Lopez CF, Akman SA, Torti FM, Torti SV, Laubenbacher R.

PLoS Comput Biol. 2017 Feb 6;13(2):e1005352. doi: 10.1371/journal.pcbi.1005352. eCollection 2017 Feb.

14.

Mitochondria and Iron: current questions.

Paul BT, Manz DH, Torti FM, Torti SV.

Expert Rev Hematol. 2017 Jan;10(1):65-79. doi: 10.1080/17474086.2016.1268047. Epub 2016 Dec 12. Review. Erratum in: Expert Rev Hematol. 2017 Mar;10(3):275.

15.

Iron and cancer: recent insights.

Manz DH, Blanchette NL, Paul BT, Torti FM, Torti SV.

Ann N Y Acad Sci. 2016 Mar;1368(1):149-61. doi: 10.1111/nyas.13008. Epub 2016 Feb 18. Review.

16.

Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Blanchette NL, Manz DH, Torti FM, Torti SV.

Expert Rev Hematol. 2016;9(2):169-86. doi: 10.1586/17474086.2016.1124757. Epub 2015 Dec 15. Review.

17.

Cytoprotective Effect of Ferritin H in Renal Ischemia Reperfusion Injury.

Hatcher HC, Tesfay L, Torti SV, Torti FM.

PLoS One. 2015 Sep 17;10(9):e0138505. doi: 10.1371/journal.pone.0138505. eCollection 2015.

18.

Targeting breast cancer with sugar-coated carbon nanotubes.

Fahrenholtz CD, Hadimani M, King SB, Torti SV, Singh R.

Nanomedicine (Lond). 2015;10(16):2481-97. doi: 10.2217/NNM.15.90. Epub 2015 Aug 21.

19.

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells.

Swanner J, Mims J, Carroll DL, Akman SA, Furdui CM, Torti SV, Singh RN.

Int J Nanomedicine. 2015 Jun 11;10:3937-53. doi: 10.2147/IJN.S80349. eCollection 2015.

20.

Hepcidin regulation in prostate and its disruption in prostate cancer.

Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, Babitt JL, Lin HY, Peehl DM, Torti FM, Torti SV.

Cancer Res. 2015 Jun 1;75(11):2254-63. doi: 10.1158/0008-5472.CAN-14-2465. Epub 2015 Apr 9.

21.

Yet another function of p53--the switch that determines whether radiation-induced autophagy will be cytoprotective or nonprotective: implications for autophagy inhibition as a therapeutic strategy.

Chakradeo S, Sharma K, Alhaddad A, Bakhshwin D, Le N, Harada H, Nakajima W, Yeudall WA, Torti SV, Torti FM, Gewirtz DA.

Mol Pharmacol. 2015 May;87(5):803-14. doi: 10.1124/mol.114.095273. Epub 2015 Feb 9.

22.

A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089.

Sharma K, Goehe RW, Di X, Hicks MA 2nd, Torti SV, Torti FM, Harada H, Gewirtz DA.

Autophagy. 2014;10(12):2346-61. doi: 10.4161/15548627.2014.993283.

23.

A systems biology approach to iron metabolism.

Chifman J, Laubenbacher R, Torti SV.

Adv Exp Med Biol. 2014;844:201-25. doi: 10.1007/978-1-4939-2095-2_10. Review.

24.

Epidemiological associations between iron and cardiovascular disease and diabetes.

Basuli D, Stevens RG, Torti FM, Torti SV.

Front Pharmacol. 2014 May 20;5:117. doi: 10.3389/fphar.2014.00117. eCollection 2014. Review.

25.

The high-molecular-weight kininogen domain 5 is an intrinsically unstructured protein and its interaction with ferritin is metal mediated.

Huhn AJ, Parsonage D, Horita DA, Torti FM, Torti SV, Hollis T.

Protein Sci. 2014 Aug;23(8):1013-22. doi: 10.1002/pro.2486. Epub 2014 May 22.

26.

IRP2 regulates breast tumor growth.

Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, Sui G, D'Agostino RB Jr, Torti FM, Torti SV.

Cancer Res. 2014 Jan 15;74(2):497-507. doi: 10.1158/0008-5472.CAN-13-1224. Epub 2013 Nov 27.

27.

Fluorinated graphene oxide; a new multimodal material for biological applications.

Romero-Aburto R, Narayanan TN, Nagaoka Y, Hasumura T, Mitcham TM, Fukuda T, Cox PJ, Bouchard RR, Maekawa T, Kumar DS, Torti SV, Mani SA, Ajayan PM.

Adv Mater. 2013 Oct 18;25(39):5632-7. doi: 10.1002/adma201301804. Epub 2013 Aug 27.

28.

Carbon nanotubes in hyperthermia therapy.

Singh R, Torti SV.

Adv Drug Deliv Rev. 2013 Dec;65(15):2045-60. doi: 10.1016/j.addr.2013.08.001. Epub 2013 Aug 8. Review.

29.

Cellular iron metabolism in prognosis and therapy of breast cancer.

Torti SV, Torti FM.

Crit Rev Oncog. 2013;18(5):435-48. Review.

30.

Application of circuit simulation method for differential modeling of TIM-2 iron uptake and metabolism in mouse kidney cells.

Xie Z, Harrison SH, Torti SV, Torti FM, Han J.

Front Physiol. 2013 Jun 7;4:136. doi: 10.3389/fphys.2013.00136. eCollection 2013.

31.

Ferritin H is a novel marker of early erythroid precursors and macrophages.

Wang W, Grier DD, Woo J, Ward M, Sui G, Torti SV, Torti FM, Beaty MW.

Histopathology. 2013 May;62(6):931-40. doi: 10.1111/his.12101.

PMID:
23611361
32.

Iron and cancer: more ore to be mined.

Torti SV, Torti FM.

Nat Rev Cancer. 2013 May;13(5):342-55. doi: 10.1038/nrc3495. Epub 2013 Apr 18. Review.

33.

Ferritin blocks inhibitory effects of two-chain high molecular weight kininogen (HKa) on adhesion and survival signaling in endothelial cells.

Tesfay L, Huhn AJ, Hatcher H, Torti FM, Torti SV.

PLoS One. 2012;7(7):e40030. doi: 10.1371/journal.pone.0040030. Epub 2012 Jul 2.

34.

Targeting Cancer Stem Cells with Nanoparticle-Enabled Therapies.

Burke AR, Singh RN, Carroll DL, Torti FM, Torti SV.

J Mol Biomark Diagn. 2012 Jul 2;Suppl 8. doi: 10.4172/2155-9929.S8-003.

35.

Hybrid 2D nanomaterials as dual-mode contrast agents in cellular imaging.

Narayanan TN, Gupta BK, Vithayathil SA, Aburto RR, Mani SA, Taha-Tijerina J, Xie B, Kaipparettu BA, Torti SV, Ajayan PM.

Adv Mater. 2012 Jun 12;24(22):2992-8. doi: 10.1002/adma.201200706. Epub 2012 May 10. No abstract available.

36.

Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27.

Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, Deng Z, Wang W, Zhang Q, Lei M, Torti SV, Akman SA, Sui G.

Am J Pathol. 2012 May;180(5):2120-33. doi: 10.1016/j.ajpath.2012.01.037. Epub 2012 Mar 20.

37.

The core control system of intracellular iron homeostasis: a mathematical model.

Chifman J, Kniss A, Neupane P, Williams I, Leung B, Deng Z, Mendes P, Hower V, Torti FM, Akman SA, Torti SV, Laubenbacher R.

J Theor Biol. 2012 May 7;300:91-9. doi: 10.1016/j.jtbi.2012.01.024. Epub 2012 Jan 23.

38.

The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy.

Burke AR, Singh RN, Carroll DL, Wood JC, D'Agostino RB Jr, Ajayan PM, Torti FM, Torti SV.

Biomaterials. 2012 Apr;33(10):2961-70. doi: 10.1016/j.biomaterials.2011.12.052. Epub 2012 Jan 14.

39.

Bioinformatics tools for cancer metabolomics.

Blekherman G, Laubenbacher R, Cortes DF, Mendes P, Torti FM, Akman S, Torti SV, Shulaev V.

Metabolomics. 2011 Sep;7(3):329-343. Epub 2011 Jan 12.

40.

Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells.

Han J, Seaman WE, Di X, Wang W, Willingham M, Torti FM, Torti SV.

PLoS One. 2011;6(8):e23800. doi: 10.1371/journal.pone.0023800. Epub 2011 Aug 19.

41.

An iron regulatory gene signature predicts outcome in breast cancer.

Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr, Torti SV, Torti FM.

Cancer Res. 2011 Nov 1;71(21):6728-37. doi: 10.1158/0008-5472.CAN-11-1870. Epub 2011 Aug 29.

42.

Determinants of the thrombogenic potential of multiwalled carbon nanotubes.

Burke AR, Singh RN, Carroll DL, Owen JD, Kock ND, D'Agostino R Jr, Torti FM, Torti SV.

Biomaterials. 2011 Sep;32(26):5970-8. doi: 10.1016/j.biomaterials.2011.04.059. Epub 2011 Jun 12.

43.

Development of iron-containing multiwalled carbon nanotubes for MR-guided laser-induced thermotherapy.

Ding X, Singh R, Burke A, Hatcher H, Olson J, Kraft RA, Schmid M, Carroll D, Bourland JD, Akman S, Torti FM, Torti SV.

Nanomedicine (Lond). 2011 Oct;6(8):1341-52. doi: 10.2217/nnm.11.37. Epub 2011 Apr 20.

44.

Differential gene expression in normal and transformed human mammary epithelial cells in response to oxidative stress.

Cortes DF, Sha W, Hower V, Blekherman G, Laubenbacher R, Akman S, Torti SV, Shulaev V.

Free Radic Biol Med. 2011 Jun 1;50(11):1565-74. doi: 10.1016/j.freeradbiomed.2011.03.002. Epub 2011 Mar 29.

45.

Ironing out cancer.

Torti SV, Torti FM.

Cancer Res. 2011 Mar 1;71(5):1511-4. doi: 10.1158/0008-5472.CAN-10-3614. Review.

46.

SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer.

Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, D'Agostino RB Jr, Miller LD, Torti FM, Torti SV.

Breast Cancer Res Treat. 2011 Oct;129(3):737-46. doi: 10.1007/s10549-010-1261-9. Epub 2010 Nov 27.

47.

Photothermal response of human and murine cancer cells to multiwalled carbon nanotubes after laser irradiation.

Fisher JW, Sarkar S, Buchanan CF, Szot CS, Whitney J, Hatcher HC, Torti SV, Rylander CG, Rylander MN.

Cancer Res. 2010 Dec 1;70(23):9855-64. doi: 10.1158/0008-5472.CAN-10-0250. Epub 2010 Nov 23.

48.

Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors.

Blish KR, Clausen KA, Hawkins GA, Garvin AJ, Willingham MC, Turner JC, Torti FM, Torti SV.

J Exp Clin Cancer Res. 2010 Nov 16;29:147. doi: 10.1186/1756-9966-29-147.

49.

Ferroportin and iron regulation in breast cancer progression and prognosis.

Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM.

Sci Transl Med. 2010 Aug 4;2(43):43ra56. doi: 10.1126/scisignal.3001127. Erratum in: Sci Transl Med. 2010 Aug 25;2(46):46er1.

50.

Ferritin H induction by histone deacetylase inhibitors.

Wang W, Di X, Torti SV, Torti FM.

Biochem Pharmacol. 2010 Aug 1;80(3):316-24. doi: 10.1016/j.bcp.2010.04.008. Epub 2010 Apr 10.

Supplemental Content

Loading ...
Support Center